ABCL — AbCellera Biologics Cashflow Statement
0.000.00%
Last trade - 00:00
- $1.13bn
- $372.48m
- $38.03m
- 46
- 24
- 56
- 37
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -2.21 | 119 | 153 | 159 | -146 |
Depreciation | |||||
Amortisation | |||||
Deferred Taxes | |||||
Non-Cash Items | 1.33 | 13.5 | 37 | 63.3 | 62.9 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 1.97 | -117 | 41.7 | 29.8 | 13.2 |
Change in Accounts Receivable | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Change in Taxes Payable | |||||
Change in Other Liabilities | |||||
Net Change in Other Assets & Liabilities | |||||
Cash from Operating Activities | 2.69 | 22.7 | 245 | 277 | -43.9 |
Capital Expenditures | -4 | -14.7 | -58.5 | -72.7 | -77.5 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -1.78 | -105 | -274 | -280 | -144 |
Acquisition of Business | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -5.78 | -120 | -332 | -353 | -221 |
Financing Cash Flow Items | — | — | -7.55 | -4.06 | -1.23 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 0.195 | 684 | -3.89 | -1.63 | 10.4 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -2.89 | 587 | -93 | -86.5 | -254 |